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Recent position statements and guidelines have raised the distinction between a true and false, age-related hypogonadism (HG) 
or late-onset hypogonadism (LOH). The former is the consequence of congenital or acquired “organic” damage of the brain 
centers or of the testis. The latter is mainly secondary to age-related comorbidities and does not require testosterone (T) therapy 
(TTh). In addition, concerns related to cardiovascular (CV) safety have further increased the scepticism related to TTh. In this 
paper, we reviewed the available evidence supporting the efficacy of TTh in non-organic HG and its long term safety. A large 
amount of evidence has documented that sexual symptoms are the most specific correlates of T deficiency. TTh is able to improve 
all aspects of sexual function independent of the pathogenetic origin of the disease supporting the scientific demonstration that 
LOH does exist according to an “ex-juvantibus” criterion. Although the presence of metabolic derangements could mitigate the 
efficacy of TTh on erectile dysfunction, the positive effect of TTh on body composition and insulin sensitivity might 
counterbalance the lower efficacy. CV safety concerns related to TTh are essentially based on a limited number of observational 
and randomized controlled trials which present important methodological flaws. When HG is properly diagnosed and TTh 
correctly performed no CV and prostate risk have been documented.
Key Words: Erectile dysfunction; Hypogonadism; Prostate; Safety; Testosterone
INTRODUCTION
Male hypogonadism (HG) is a medical condition char-
acterized by a failure of the testis to produce and release 
adequate concentrations of its products, i.e., sperms and 
sex steroids. It can be congenital or acquired. The latter 
form is far more common than the former and it is usually 
apparent during adulthood [1]. Adult-onset HG is mainly 
related to aging itself and to the presence of comorbid con-
ditions, increasingly more prevalent in ageing men, which-
might impair the regular functioning of the testis and of its 
controllers, such as the pituitary (follicular stimulating hor-
mone [FSH] and luteinizing hormone [LH]) and hypothal-
amus (gonadotropin-releasing hormone [GnRH]) [2-4]. 
Among these potentially impairing conditions, there are 
metabolic disturbances which are very common in the 
general population, such as obesity, metabolic syndrome 
(MetS) and type 2 diabetes mellitus (T2DM) [1,4-6]. The 
mechanisms by which an altered metabolism could im-
pair the hypothalamic-pituitary-gonadal axis is still un-
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clear, but the possibility that a low-grade hypothalamic in-
flammation can cause a disruption in GnRH formation or 
action is growing [7]. Adult-onset HG- or more commonly 
defined late-onset hypogonadism (LOH) is a condition 
characterized by a constellation of unspecific symptoms 
and signs, often superimposable to those of the aging proc-
ess per se. Among those, sexual dysfunctions appear as the 
mostly specific symptoms characterizing the androgen 
deficiency. In fact, there is considerable evidence that tes-
tosterone (T) plays a crucial role in regulating male sexual 
function [8-11]. The European Male Aging Study (EMAS), 
a population based survey performed on more than 3,400 
men recruited from 8 European centres, has clearly shown 
that sexual symptoms—i.e., decreased frequency of sexual 
thoughts, decreased morning erections, and erectile dys-
function (ED)—are the most sensitive and specific symp-
toms in identifying patients with low T [12]. Similar results 
have been more recently reported by the T Trials [13], a 
randomized controlled trial performed in 788 commun-
ity-dwelling men recruited from 12 sites in the United 
States, and by Rastrelli et al [14] in a large sample of men 
seeking medical care for sexual dysfunction. It has been 
proposed that when the presence of sexual symptoms is 
associated with a biochemical deficiency of circulating T 
a diagnosis of symptomatic LOH can be made. In the 
European adult population, 2% of the sample satisfy these 
criteria, whereas 17% demonstrated an isolated T defi-
ciency (total T ＜11 nmol/L) [12]. 
As in all endocrine disorders, the goal of treatment of 
HG is to restore the deficient glandular function. If fertility 
is the issue and the testis is under-stimulated because of a 
gonadotropin deficiency, FSH and LH administration is 
recommended. In all the other cases, testosterone therapy 
(TTh) is the most convenient choice [15]. Quite surpris-
ingly, in the United States, after a 2015 Food and Drug 
Administration (FDA) position statement (http://www.fda. 
gov/Drugs/DrugSafety/ucm436259.htm), TTh is approved 
only for congenital HG or for acquired forms due to an 
“organic” damage to the brain centres or to the testis. 
Hence, either comorbidity-associated or age-related HG 
are not recognized as true pathological conditions need-
ing a pharmacological intervention. The recently pub-
lished Guidelines of the Australian Endocrine Society [16] 
fully endorsed the FDA’s position, suggesting that remov-
ing the underlying metabolic conditions, such as losing 
weight, must be the optimal therapeutic strategy for treat-
ing obesity-associated HG, and that TTh is not justified in 
such conditions. Hence, the concept that a distinction be-
tween a true HG (classicor organic HG) and a false, age-re-
lated, HG (the so-called low T syndrome or andropause or 
pseudohypogonadism) is raising [16]. It is interesting to 
note that among more than 4,000 subjects seeking medi-
cal care at an endocrine unit for sexual dysfunction, we 
found a large proportion of HG subjects (i.e., 20%, de-
fined as total T below 10.4 nmoles/L [17]). Of this, only 
15% of all causes of HG fulfil the criteria of “classic HG”, 
whereas the large majority presents comorbidities, includ-
ing obesity, MetS and T2DM [17]. According to the FDA’s 
position and the Australian recommendations, all these 
symptomatic HG subjects should be left untreated, with a 
pharisaic advice of conducting a healthier lifestyle. 
Scepticism and even reluctance to start an androgen sup-
plementation is essentially based on two kinds of consid-
erations regarding TTh: 1) lack of efficacy in non-organic 
HG and 2) side effects. In this review we will analyse evi-
dence underlying these believes. 
LACK OF EFFICACY OF TESTOSTERONE 
THERAPY IN NON-ORGANIC 
HYPOGONADISM
There is no controversy about the fact that losing weight 
is an effective strategy to overcome T deficiency in obese 
subjects. In a previous meta-analysis we demonstrated 
that either lifestyle changes or bariatric surgery are effec-
tive in raising gonadotropin and T secretion [1,18]. 
Besides male HG, T2DM is another obesity-associated 
medical condition with a growing prevalence in the gen-
eral population worldwide [19]. Also for T2DM, weight 
reduction and change in lifestyle are the frontline therapy, 
but it is inconceivable to negate effectiveness of pharma-
cological antidiabetic intervention just because the dia-
betic patient is also obese [19]. In fact, metformin admin-
istration is strongly suggested in newly diagnosed T2DM, 
regardless of any lifestyle intervention [19]. Why, along 
with lifestyle changes, is pharmacological treatment with 
metformin advised in T2DM and TTh is not in HG? Maybe 
because T2DM is a more “organic” condition than HG? It 
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Table 1. Similarities between T2DM and LOH
Variable T2DM LOH
Prevalence (%) 2∼15 2∼15
Association with aging Yes Yes
Association with obesity Yes Yes
Association with sexual dysfunction Yes Yes
Symptom specificity No/mild No/mild
Biochemical threshold for definition Yes Yes
Well-known (genetic or organic) 
etiological factors (%)
1 15
Improved by weight loss or lifestyle 
changes 
Yes Yes
Improved by a specific therapy Yes Yes
T2DM: type 2 diabetes mellitus, LOH: late-onset hypogonadism.
is interesting to note that the well-defined organic con-
ditions leading to diabetes represent less than 1% of all 
cases of diabetes [19]. All the other cases are multi-facto-
rial conditions that may or may not have a genetic back-
ground, still largely unidentified. This does not mean that 
diabetes exists in all cases or that it should not be promptly 
treated. Similarities between T2DM and male HG are 
schematized in Table 1.
The fact that symptoms of androgen deficiency in adult-
hood often overlap with those characteristics of the aging 
process (and its associated comorbidities) further compli-
cates the debate. However, T2DM also is a condition char-
acterized by unspecific symptoms, often overlapping with 
those of the aging process (Table 1). Interestingly, criteria 
for diagnosis of diabetes are based only on well-defined al-
terations of biochemical parameters, such as increased 
glycaemia or HbA1c, independently of symptoms [19]. 
This is not the case of HG. In fact, in LOH, all the Scientific 
Societies indicate that a reduction of circulating T is not 
enough for defining the disease. Specific symptoms must 
be present along with T deficiency. Symptoms of an-
drogen deficiency include psychological (i.e., depres-
sion), physical (i.e., fatigue) and sexual concerns [20-22]. 
Recently, Millar et al [23] reported a review of available lit-
erature to estimate the accuracy and operating character-
istics of signs and symptoms for predicting low T in aging 
men. They found a weak correlation between signs, symp-
toms and T levels, uncertainty about what threshold T lev-
els should be considered low for aging men and wide var-
iation in estimated prevalence of the condition [23]. In ad-
dition, all relationships with symptoms are relatively poor 
in terms of sensitivity and specificity. However, as stated 
before, the EMAS study has clearly shown that sexual 
symptoms, and in particular their syndromic association, 
allow a better identification of the so-called LOH [12,24]. 
Similar results were recently reported by us in a large co-
hort (n=4,890) of subjects consulting for ED at the 
University of Florence (UNIFI) [14]. However, in both the 
EMAS [12] and UNIFI [14] cohorts, Loess curve analysis 
did not indicate a clear-cut threshold where the associa-
tion between sexual symptoms and hormonal deficiency 
is apparent, with a total T below 11 and 10.4 nmoles/L be-
ing the best indicators of sexual symptomatology, respec-
tively. In contrast, in the EMAS study [12], the relationship 
between T deficiency and psychological and physical 
symptoms was rather poor or even absent. 
Considering that sexual symptoms are the most genuine 
correlates of T deficiency, it is interesting to evaluate 
whether or not treating this deficiency is able to restore 
sexuality. If this is the case, we have the scientific demon-
stration that the so-called LOH does exist according to an 
“ex-juvantibus” criterion. A recent systematic qualitative 
review on the effect of TTh on several outcomes con-
cluded that T did not show consistent benefit for sexual 
function [25]. However, the same Authors declared that 
sexual function was evaluated using different tools [25]. In 
addition, they included both eugonadal and hypogonadal 
subjects in the analysis [25]. Hence, their conclusions 
(based only on a personal perspective) are not derived 
from validated statistical methods. In contrast with the last 
report, we previously documented, using a meta-analytic 
method, that TTh is superior, when compared to placebo, 
in improving all aspects of sexual function [26]. Table 2 
summarizes the main results of the meta-analysis. The out-
comes observed were independent of age but indirectly 
related to the levels of T at enrolment. Furthermore, as ex-
pected, the effects of TTh were lower in the presence of 
vascular damage, such as in the case of T2DM [26]. 
Considering that metabolic conditions are often asso-
ciated with relatively milder forms of T deficiency, it is 
possible that a lower apparent efficacy of TTh in T2DM is 
due to higher T baseline levels [27]. In addition, the miti-
gated effect of TTh in T2DM is also in line with the lower 
efficacy of all available treatment for ED in subjects with 
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Table 2. Effect size (with 95% confidence interval) in several sexual parameters across randomized controlled trials evaluating 
the effect of testosterone treatment vs. placebo
Sexual parameter No. of trials included 
No. of patients 
included Outcome
Erectile function component
  Overall erectile function componenta 24 1,473 0.82 [0.47∼1.17]*
  Overall sexual-related function componentb 19 1,341 0.75 [0.37∼1.12]**
  Sleep-related erections 10 436 0.87 [0.47∼1.27]**
Libido component 
  Overall libido component 17 1,111 0.81 [0.47∼1.17]**
Orgasm component 
  Overall orgasmic component 10 677 0.68 [0.34∼1.02]**
Other sexual parameters
  Frequency of intercourse 10 327 0.75 [0.33∼1.16]**
  Overall sexual satisfaction 9 618 0.80 [0.41∼1.20]**
  Overall sexual function 10 990 0.67 [0.22∼1.12]**
*p＜0.001, **p＜0.0001. aIncluding coital and non coital erections; bOnly coital erections considered.
Adapted from Corona et al (J Sex Med 2014;11:1577-92) [26].
diabetes, due to the presence of the diabetes-associated 
chronic complications, which are not necessarily due to 
an androgen deficiency [21,22,28,29]. Although the pres-
ence of metabolic derangements could limit the efficacy 
of TTh on ED, the positive effect of TTh on body composi-
tion and insulin sensitivity [30-32] might counterbalance 
the lower efficacy. Our meta-analysis confirmed epide-
miological observation showing that sexual dysfunctions 
are a hallmark of HG, because TTh can significantly im-
prove them. The vast majority of the subjects enrolled in 
the included RCTs are not those with “classic” HG. For ex-
ample, in the T trial [33] 63% of the participants were 
obese and all were 65 years or older without apparent rea-
son for HG other than age. In conclusion, there is robust 
evidence that all the forms of symptomatic HG should be 
treated irrespective to their “organic” or “non-organic” 
(metabolic) origin because most specific symptoms (sexual 
ones) are improved. 
LONG TERM SAFETY OF TESTOSTERONE 
THERAPY
T esters have been available for almost 80 years; how-
ever, only over the past two decades has the introduction 
and use of newer, user-friendly preparations dramatically 
expanded the market [4]. Since their introduction to the 
market, the risk of prostate cancer (PC) was considered the 
most feared side effect related to the use of T preparations. 
In addition, quite recently,conflicting data have raised the 
possible relationship between TTh and increased car-
diovascular (CV) risk. In the following section, these two 
aspects will be analyzed in detail.
1. Cardiovascular events during testosterone therapy
Over the last four years, there have been mounting con-
cerns that TTh may increase the risk for CV events, such as 
heart attacks and strokes. These concerns were essentially 
based on two retrospective pharmaco-epidemiological 
papers published between the end of 2013 and the begin-
ning of 2014 [34,35]. Salient pitfalls related to these re-
ports have been commented elsewhere [17,36,37]. 
Although these studies presented many flaws, due to their 
retrospective design and to the little information on the da-
tabases, they received much attention in the lay media, in-
cluding The New York Times. Other studies report that 
low T levels in older men are associated with increased CV 
risk and that TTh may have CV benefits [17,36,37]. In par-
ticular, besides the two aforementioned observational 
studies, several other reports were published either pre-
viously or thereafter [34,35,38-48]. Overall, 13 studies 
have been published so far, including 194,609 cases and 
1,195,582 controls (Table 3). Among them, six studies 
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Table 3. Descriptive characteristics of the available pharmaco-epidemiological studies evaluating the impact of testosterone
treatment on forthcoming overall mortality or myocardial infarction












Shores et al (2012) 
[38]
62.1 398/633 81 TT ＜250 ng/dL 
(8.7 nmol/L)
T treatment vs. 
no treatment
↓ NA
Finkle et al (2014) 
[35]




Muraleedharan et al 
(2013) [39]
45∼59 64/174 16.5 TT ＜300 ng/dL 
(10.4 nmol/L)
T treatment vs. 
no treatment
↓ NA 
Vigen et al (2013) 
[34]
63.4 1,223/7,486 110 TT ＜300 ng/dL 
(10.4 nmol/L)
T treatment vs. 
no treatment
↑b ↑b
Baillargeon et al 
(2014) [40]
≥66 6,355/19,065 182 NA TTh prescription 
vs. no TTh 
prescription
NA ↔
Eisenberg et al (2015) 
[41]
54.4 284/225 520 NA TTh prescription 
vs. no TTh 
prescription
↔ NA
Etminan et al (2015) 
[42]
70.4 30.066/120.264 145 NA TTh prescription 
vs. no TTh 
prescription
NA ↔ 
Ramasamy et al 
(2015) [43]
74.3 153/64 191 TT ＜300 ng/dL 
(10.4 nmol/L)
T treatment vs. 
no treatment
↔ NA
Sharma et al (2015) 
[44]
66.2 60.632/21.380 304 TT lower than the 
local laboratory 
reference range 
T treatment vs. 
no treatment
↓c ↓c
Tan et al (2015) [45] 20∼86 19.968/821.725 72 TT ＜350 ng/dL 
(12.0 nmol/L)
TTh prescription 
vs. no TTh 
prescription
NA ↓
Maggi et al (2016) 
[46]
59.1 759/249 156 TT lower than the 
local laboratory 
reference range
T treatment vs. 
no treatment
↔ ↔ 
Wallis et al (2016) 
[47]
≥65 10.311/28.029 260 NA TTh prescription 
vs. no TTh 
prescription
↓ NA 












TT: total testosterone, NA: not available, T: testosterone, TTh: testosterone therapy, PDE5i: phosphodiesterase type 5 inhibitor, 
↓: reduced risk, ↑: increased risk, ↔: unchanged risk.
aValues are presented as mean only or mean range.
bComposite of all-cause mortality, acute myocardial infarction, and ischemic stroke. 
cNormalized treated vs. untreated. 
dComposite cardiac events: myocardial infarction, coronary revascularization, unstable angina, and sudden cardiac death. 
compared the effect of TTh in HG men vs. untreated HG 
men. In the other seven studies, the effect of T prescription 
was compared to subjects who were not prescribed T. In 
the latter cases limited information regarding the T levels 
was available (Table 3). Overall, an increased CV risk was 
reported only in the Vigen et al [34] and Finkle et al [35] 
whereas in all other reports a neutral or beneficial effect of 
TTh was found (Table 3). In particular, in 2017 the largest 
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Table 4. Comparisons of the available meta-analyses evaluating the relationship between testosterone therapy and CV risk
Variable
Study





Balsells et al 
(2010) [51]










et al (2017) 
[56]
No. of trials included 19 30 51 27 75 35 45 39
No. of patients analyzed 1,084 1,642 2,679 2,944 5,464 3,703 5,328 5,441
Inclusion criteria Yes No Yes No Yes No Yes No Yes No Yes No Yes No Yes No
  Primary end point MACE 
incidence
× × × × × × × ×
  Primary end point CV 
event other than MACE
× × × × × × × ×
  Time restriction 
(＞12 wk)
× × × × × × × ×
  Age restriction (≥45 y) × × × × × × × ×
CV event analysis
  All CV events × × × × × × × ×
  Serious adverse events 
(including MACE)
× × × × × × × ×
  MACE × × × × × × × ×
  AMI × × × × × × × ×
  Acute coronary 
syndrome
× × × × × × × ×
  Coronary by-pass surgery × × × × × × × ×
  Stroke × × × × × × × ×
  New heart failure × × × × × × × ×
  Arrhythmias × × × × × × × ×
  CV mortality × × × × × × ×
  Overall mortality × × × × × × × ×
× indicates if Yes or No. 
CV: cardiovascular, MACE: major adverse cardiovascular events, AMI: acute myocardial infarction.
observational study published so far became available 
[48]. The study evaluated 44,335 male patients at Kaiser 
Permanente medical centers in Northern and Southern 
California who had been diagnosed with androgen defi-
ciency between January 1, 1999 and December 31, 2010. 
Of these, 8,808 men were treated with TTh, whereas 
35,527 were never dispensed T. Among men with an-
drogen deficiency, those who were dispensed T pre-
scriptions were associated with a lower risk of CV out-
comes overa median follow-up of 3.4 years. Despite their 
strengths, observational studies present important limi-
tations including: selection, information, and confound-
ing biases. In addition, usually limited information regard-
ing the level of T before and during TTh are available. 
Hence, caution is needed when evaluating results report-
ing small differences. 
Systematic reviews and meta-analyses are often consid-
ered as the highest level of evidence for evaluating inter-
ventions in healthcare and as a particularly useful tool to 
address questions for which multiple data sources are 
conflicting. Eight systematic meta-analyses on the associa-
tion between TTh and CV risk have been published so far 
(Table 4) [49-56]. The number of included trials ranged 
from 19 to 75 including from 1,084 to 5,464 subjects. 
Seven meta-analyses [49,50,52-56] reported outcomes on 
aggregate CV events, whereas one [51] investigated dis-
aggregate events. Forest plots of estimated odds ratio (95% 
confidence intervals) for aggregate or disaggregate CV 
events, as derived from available meta-analyses investigat-
ing the effects of TTh on CV risk, are summarized in Fig. 1. 
Only Xu et al [52] reported an increased CV risk related to 
TTh. However, it is important to emphasize that the latter 
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Fig. 1. Forest plot of estimated odds
ratio (OR) (95% confidence inter-
vals) for aggregate or disaggregate 
cardiovascular disease (CVD) events
as derived from available meta- 
analyses of randomized controlled 
trials on the effect of testosterone 
therapy (TTh) vs. placebo. CV: 
cardiovascular, MACE: major 
adverse cardiovascular events, AMI:
acute myocardial infarction, NR: 
not reported, MH-OR: Mantel- 
Haenszed odds ratio, LL: lower 
limits, UL: upper limits.
authors used, for their analysis, “composite CV-related 
events”, including all investigator-reported adverse events 
assigned to the CV system. Hence, cases of “peripheral 
edema” and “self-reported syncope” were also allocated 
to the category CV events, leading to an artificial increase 
of the overall number of events [52]. Conversely, all other 
meta-analyses published so far did not report an increased 
CV risk related to TTh either when aggregated or dis-
aggregate CV were considered (Fig. 1). It is important to 
recognize that all available trials included in the meta- 
analyses have a relatively short duration, lasting atmost 
three years. Therefore, although there is no clear sign of 
risk in the short term, no information is available on possi-
ble long-term effects.
2. Prostate safety
Prostate safety remains one of the most important con-
troversial issues of TTh since, historically, PC has been as-
72   World J Mens Health Vol. 35, No. 2, August 2017
Fig. 1. Continued.
sociated with an increased androgenicity [57,58]. Hence, 
clinicians and regulatory agencies are all concerned by 
the fact that TTh could cause or promote PC. 
Much evidence published in the two last decades has 
substantially better clarified the role of T in regulating pros-
tate growth and differentiation [57-61]. Epidemiological 
studies have failed to find an association between endoge-
nous T levels and risk of PC. In particular, the most recent 
meta-analysis—that pooled worldwide data from 20 pro-
spective studies including 5,623 PC cases and 14,604 
controls and mean follow-up of 10 years—reports a rela-
tive risk of PC of 0.99 [0.96;1.02] for an increase of 5 
nmol/L of T [62].
In line with these data it has been demonstrated that an-
drogen-dependency of prostate growth is evident only in 
the hypogonadal condition, but not in the eugonadal state. 
In fact, according to Morgentaler and Traish’s “saturation 
hypothesis”, the human prostate androgen receptors are 
“saturated” by the circulating androgens and therefore 
rather insensitive to further T increase, such as those de-
rived from TTh in cases of mild HG [63]. Accordingly, in 
vitro studies have documented that prostate cell pro-
liferation increased at low T concentration but at higher 
concentrations even logarithmic increases in T could not 
enhance growth [58]. This observation can explain the 
positive effect of androgen deprivation therapy (ADT) in 
androgen sensitive advanced PC and the possible re-
currence as the androgen levels normalize from castrated 
levels after treatment [58]. 
The aforementioned evidence was further confirmed by 
the analysis of interventional trials. Since 2005, seven sys-
tematic meta-analyses on the association between TTh 
and prostate safety are available and their results are sum-
marized in Table 5 [49,51,62,64-67]. The number of trials 
considered ranged from 4 to 26 including from 1,084 to 
5,464 subjects. As expected, TTh was associated with a 
significant short term increase in prostate-specific antigen 
(PSA) levels [64,65] or prostate volume (Fig. 2) [67]. 
Accordingly, we previously demonstrated that low PSA 
could be considered a reliable biochemical marker of re-
duced bioactive circulating androgens in subjects consult-
ing for sexual dysfunction, providing an index of low an-
drogenization, which includes T-activated post-receptor 
downstream events [68,69]. No increased risk in interna-
tional prostate symptom score (IPSS) worsening, in de-
tection of abnormal PSA levels or in developing PC was 
observed (Fig. 2). Interestingly, by evaluating data from 
observational studies based on the use of long-term in-
jectable T undecanoate, we previously observed an im-
provement of IPSS, particularly when the analysis was re-
stricted to those studies enrolling only hypogonadal sub-
jects at enrolment [32]. In the last few years, we have pro-
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Table 5. Comparisons of the available meta-analyses evaluating the relationship between testosterone therapy and prostate safety
Variable Calof et al (2005) [49]
Fernández-





Cui et al 
(2014) [65]
Guo et al 
(2016) [67]
Kang et al 
(2015) [66]
Boyle et al 
(2016) [62]
No. of trials included 19 51 16 22 16 15 27
No. of patients analyzed 1,084 2,679 1,030 2,351 1,921 1,124 2,213
Inclusion criteria Yes No Yes No Yes No Yes No Yes No Yes No Yes No
  Primary end point prostate safety × × × × × × ×
  Data presented according to trial 
duration
× × × × × × ×
  Time restriction (＞12 wk) × × × × × × ×
  Time restriction (＞24 wk) × × × × × × ×
  Age restriction (≥45 yr) × × × × × × ×
Prostate adverse event analysis
  PSA change × × × × × × ×
  Prostate volume × × × × × × ×
  IPSS × × × × × × ×
  Abnormal PSA × × × × × × ×
  Prostate biopsy × × × × × × ×
  Prostate cancer × × × × × × ×
× indicates if Yes or No.
PSA: prostatic specific antigen, IPSS: international prostatic symptoms score.
Fig. 2. Forest plot of estimated odds
ratio (OR) (95% confidence intervals)
for prostate adverse events as de-
rived from available meta-analyses
of randomized controlled trials on 
the effect of testosterone therapy 
(TTh) vs. placebo. PSA: prostatic 
specific antigen, IPSS: international
prostatic symptoms score, NR: not 
reported, LL: lower limits, UL: 
upper limits.
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duced both experimental and clinical data suggesting a 
link between reduced T levels, prostate inflammation and 
benign prostatic hyperplasia (BPH) [59-61]. The under-
lying pathogenetic mechanisms are not completely under-
stood, but an intriguing hypothesis indicates a close link 
between obesity and its related metabolic derangement 
(particularly dyslipidemia), reduced T and an increased 
risk of BPH and its related inflammatory component 
[59-61,70].
CONCLUSIONS
A large body of evidence has documented that sexual 
symptoms are the most specific correlates of T deficiency. 
TTh is able to improve all aspects of sexual function in-
dependent of the pathogenetic origin of the disease sup-
porting the scientific demonstration that the so-called 
LOH does exist according to an “ex-juvantibus” criterion. 
Although the presence of metabolic derangements could 
mitigate the efficacy of TTh on ED, the positive effect of 
TTh on body composition and insulin sensitivity might 
counterbalance the lower efficacy. CV safety concerns re-
lated to TTh are essentially based on a limited number of 
observational and randomized controlled trials which 
present important methodological flaws. When HG is 
properly diagnosed and TTh correctly performed no CV 
and prostate risk have beendocumented. 
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